Sugi Predict

Sugi Predict / Compounds / SCHEMBL1243217

SCHEMBL1243217

SCHEMBL1243217

c1ccc(OCc2nnn[nH]2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 7/20 0.47
▸ NPC1 O15118 5/20 0.47
▸ SMN1; SMN2 Q16637 3/20 0.47
▸ TP53 P04637 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ KCNH2 Q12809 2/20 0.44
▸ DAO P14920 1/20 0.44
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ RXFP1 Q9HBX9 1/20 0.43
▸ PKM P14618 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ NLRP3 Q96P20 1/20 0.42
▸ MAOA P21397 1/20 0.41
▸ MAOB P27338 1/20 0.41
▸ NISCH Q9Y2I1 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ APP P05067 1/20 0.39
▸ KCNA3 P22001 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5757984 0.82 NPC1 (0.32) RAB9ANPC1SMN1; SMN2TP53TSHR
SCHEMBL13645908 0.82 SMN1; SMN2 (0.48) RAB9ANPC1SMN1; SMN2TP53KCNH2
SCHEMBL12844914 0.82 MAOB (0.44) RAB9ANPC1SMN1; SMN2TSHRKMT2A
SCHEMBL3060051 0.80 MAOB (0.51) RAB9ANPC1SMN1; SMN2TP53TSHR
SCHEMBL12015680 0.78 APP (0.46) APP
SCHEMBL20782346 0.78 RXRA (0.42) RAB9ANPC1SMN1; SMN2TP53KCNH2
SCHEMBL7446675 0.78 CYP4F2 (0.46) —
SCHEMBL10546763 0.78 CYSLTR1 (0.62) CYSLTR2CYSLTR1
SCHEMBL9329216 0.77 MAOB (0.50) MAOB
SCHEMBL14021516 0.77 LTA4H (0.46) RAB9ANPC1SMN1; SMN2TP53MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9381238-B2 Method for improving the production of influenza viruses and vaccine seeds UNIVERSITY OF DUNDEE (GB) 2016-07-05 — — US claimed
US-20130315954-A1 METHOD FOR IMPROVING THE PRODUCTION OF INFLUENZA VIRUSES AND VACCINE SEEDS UNIVERSITY OF DUNDEE (GB) 2013-11-28 — — US claimed
EP-2635302-A1 METHOD FOR IMPROVING THE PRODUCTION OF INFLUENZA VIRUSES AND VACCINE SEEDS University of Dundee (GB) 2013-09-11 — — EP claimed
WO-2012059696-A1 METHOD FOR IMPROVING THE PRODUCTION OF INFLUENZA VIRUSES AND VACCINE SEEDS UNIVERSITY OF DUNDEE (GB) 2012-05-10 — — WO claimed
US-11897918-B2 Compositions and methods to increase production Seqirus UK Limited (GB) 2024-02-13 — — US disclosed
CN-106471119-B Compositions and methods for increasing yield 思齐乐 2020-11-10 — — CN disclosed
EP-2488028-B1 SUBSTITUTED PIPERIDINES THAT INCREASE P53 ACTIVITY AND THE USES THEREOF MERCK SHARP & DOHME (US) 2020-08-19 — — EP disclosed
US-10689331-B2 IDO inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2020-06-23 — — US disclosed
EP-3131578-B1 COMPOSITIONS AND METHODS TO INCREASE PRODUCTION SEQIRUS UK LTD (GB) 2020-06-03 — — EP disclosed
CN-104945382-B Substituted piperidines that increase p53 activity and uses thereof 默沙东公司 2020-02-07 — — CN disclosed
US-20200040040-A1 COMPOSITIONS AND METHODS TO INCREASE PRODUCTION NOVARTIS (CH) 2020-02-06 — — US disclosed
US-20190002402-A1 IDO INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2019-01-03 — — US disclosed
US-5750754-A TERTIARY BUTYL 3-METHYL-4-SUBSTITUTED BUTYRATE; CHEMICAL INTERMEDIATES FOR ANTICAOGULANT DRUGS ZENECA LIMITED (GB) 1998-05-12 — — US disclosed
US-5563141-A INHIBIT CELL ADHESION FOR EXAMPLE, PLATELET AGGRE GATION ZENECA LIMITED (GB) 1996-10-08 — — US disclosed
EP-0690847-A1 HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS ZENECA LIMITED (GB) 1996-01-10 — — EP disclosed
WO-1994022835-A2 HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS ZENECA LIMITED (GB) 1994-10-13 — — WO disclosed
US-5274000-A 2-alkyl-3-carboxyalkylene or amidoalkyleneoxy-1,4-phenylene KOTOBUKI SEIYAKU COMPANY LIMITED (JP) 1993-12-28 — — US disclosed
US-5175184-A Diuretics KOTOBUKI SEIYAKU COMPANY LIMITED (JP) 1992-12-29 — — US disclosed
US-5004750-A Diuretics KOTOBUKI SEIYAKU COMPANY LIMITED (JP) 1991-04-02 — — US disclosed
US-4797415-A DIURETICS FOR GOUT KOTOBUKI SEIYAKU COMPANY LIMITED (JP) 1989-01-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130315954-A1 METHOD FOR IMPROVING THE PRODUCTION OF INFLUENZA VIRUSES AND VACCINE SEEDS MDM2, TP53, TP53BP1 RAB9A 2905/4885NPC1 3925/4885SMN1; SMN2 4358/4885
US-20200040040-A1 COMPOSITIONS AND METHODS TO INCREASE PRODUCTION MRPL21, CHLSN, MAX RAB9A 1701/4885NPC1 1723/4885SMN1; SMN2 3641/4885
US-20190002402-A1 IDO INHIBITORS IDO1, IDO2, INMT RAB9A 3625/4885NPC1 2825/4885SMN1; SMN2 4280/4885
US-11897918-B2 Compositions and methods to increase production MRPL21, CHLSN, MAX RAB9A 1701/4885NPC1 1723/4885SMN1; SMN2 3641/4885
US-10689331-B2 IDO inhibitors IDO1, IDO2, INMT RAB9A 3625/4885NPC1 2825/4885SMN1; SMN2 4280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.